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Abstract
Background: Stereotactic Ablative Radiotherapy (SABR) is an effective treatment that improves local control for
many tumours. However, the role of SABR in gynecological cancers (GYN) has not been well-established. We
hypothesize that there exists considerable variation in GYN-SABR practice and technique. The goal of this study is
to describe clinical and technical factors in utilization of GYN-SABR among 11 experienced radiation oncologists.
Materials and methods: A 63 question survey on GYN-SABR was sent to 11 radiation oncologists (5 countries)
who have published original research, conducted trials or have an established program at their institutions.
Responses were combined and analyzed at a central institution.
Results: Most respondents indicated that salvage therapy (non-irradiated or re-irradiated field) for nodal (81%) and
primary recurrent disease (91%) could be considered standard options for SABR in the setting of inability to
administer brachytherapy. All other indications should be considered on clinical trials. Most would not offer SABR as
a boost in primary treatment off-trial without absolute contraindications to brachytherapy. Multi-modality imaging
is often (91%) used for planning including PET, CT contrast and MRI. There is a wide variation for OAR tolerances
however small bowel is considered the dose-limiting structure for most experts (91%). Fractionation schedules
range from 3 to 6 fractions for nodal/primary definitive and boost SABR.
Conclusions: Although SABR has become increasingly standard in other oncology disease sites, there remains a
wide variation in both clinical and technical factors when treating GYN cancers. Nodal and recurrent disease is
considered a potential indication for SABR whereas other indications should be offered on clinical trials. This study
summarizes SABR practices among GYN radiation oncologists while further studies are needed to establish
consensus guidelines for GYN-SABR treatment.
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Background
Radiation plays an important role in the treatment of
gynecological cancers. In both the definitive and adju-
vant setting, local radiotherapy to pelvic primaries
and lymph nodes have been shown to improve local
control and outcome in different gynecological malig-
nancies such as cervical, uterine and vulvovaginal tu-
mours [1–6]. Brachytherapy has been a mainstay of
gynecological (GYN) cancer treatments as the high
conformality of this technique allows for high dose
treatment to the central tumour while sparing nearby
organs-at-risk [7]. Because of the effectiveness of
brachytherapy and its importance in outcome in GYN
cancer treatment, the role of stereotactic ablative
radiotherapy (SABR) has not been well-studied.
SABR is well-known to be an effective radiation treat-
ment technique for multiple tumour types and for vari-
ous indications. Malignancies of the the lung, liver,
brain, and the spine have well-established protocols and
consensus in regard to treatment indications, technique
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and dose [8, 9]. SABR is defined as the delivery of abla-
tive doses of radiation to localized targets sites using
highly conformal techniques and is achieved by very ro-
bust immobilization, organ motion management, on-
board imaging and advanced radiotherapy treatment
planning.
A systematic review of SABR treatment for GYN can-
cers showed that this technique, although not standardly
indicated, has been used for multiple GYN indications in
a small number of single arm prospective clinical trials
and several smaller retrospective series [10–12]. These
include primary boost treatment for cervical and uterine
cancers, adjuvant vaginal treatment and nodal or pri-
mary salvage treatment. The treatment has been gener-
ally well-tolerated with acceptable toxicities in the GYN
setting [10]. However, it is apparent that clinical indica-
tions and techniques in these studies are vastly different
and a standardized approach has not been adopted for
GYN tumours worldwide. The goal of this study is to
determine clinical and technological factors of GYN
SABR among 11 radiation oncologists at 11 specialized
SABR centres.
Material and methods
A 63 question survey was sent to 11 radiation oncol-
ogists who practice and have published on GYN
SABR in 5 different countries. Participating institu-
tions included Department of Radiation Oncology,
Sunnybrook Health Science Centre and Odette Can-
cer Centre, (OCC: Toronto, Ontario, Canada), Na-
tional Cancer Institute, (NIH: Rockville, MD, USA),
Delaware County Memorial Hospital/Philadelphia
Cyberknife (PhilCyber: Drexel Hill, PA), twenty-first
Century Oncology (21Century: Fort Myers, FL,
USA), University Hospital Zuerich, (ZUR: Zuerich,
Switzerland), Department of Radiation Oncology,
Northeastern Radiation Oncology, (NE: Glen Falls,
NY), Soonchunhyang University Seoul Hospital (SC:
Seoul, Korea), Institut Oncologic Teknon, (TEK: Bar-
celona, Spain), Case Western Reserve University
School of Medicine, (CASE: Cleveland, OH), Univer-
sita degli Studi di Messina, (MI: Messina, Italy), Uni-
versity of Texas Southwestern Medical Center,
(UTSW: Dallas, TX). The survey included 63 ques-
tions in 5 parts. Topics of the questionnaire were
pertaining to clinical and technological factors of
GYN SABR technique. These included questions on
the indications for GYN SABR, the eligibility criteria,
pre-treatment investigation, treatment planning
protocol, target delineation, dose targets and con-
straints and treatment response evaluation. Surveys
were sent via e-mail and responses were collected
and evaluated at a central institution (OCC). The
questionnaire was completed during the period of
January 2017 to March 2017. Responses were pre-
sented as percentages of agreement for each question
among the 11 participants.
Results
Eligibility and indications
All participants completed the survey. The median num-
ber of GYN SABR patients treated in total per partici-
pant was 40 (5–125). SABR for GYN malignancies is
used most commonly for recurrent disease (nodal or pri-
mary) in patients who have had prior radiation and/or
have contraindications to brachytherapy or surgery (64–
91%). Salvage pelvic and para-aortic nodal SABR was
highly cited in this international survey as a common
practice in patients with locally advanced gynecological
cancers without prior radiation (82%).
SABR is not typically used as an alternative to brachy-
therapy but could be considered in the setting of clinical
trials (64%). Primary SABR boost can be used when
there is a contraindication to brachytherapy (73%). The
indications of GYN SABR from the survey are summa-
rized in Table 1.
Applying a size constraint for GYN SABR was com-
mon in setting of cervical/vaginal boost and nodal SABR
(64%). Tumour size constraints varied between 5 and 8
cm or 90–600 cc. Nodal size limits varied from 3 to 5
cm or 125–600 cc. An age restriction is not common for
SABR treatment in GYN cancers (91%) however some
respondents felt that patients should generally have a
performance status of 0–2 ECOG or KPS (64%).
It is recommended that pathological confirmation is
obtained prior to starting SABR treatment (82%), how-
ever, histological subtype (eg. squamous cell carcinoma
vs. adenocarcinoma) does not typically influence SABR
treatment decision. (100%).
Contraindications to GYN SABR include brachyther-
apy eligibility (64%), tumour in close proximity to small
bowel (46%), and previous high dose radiation/brachy-
therapy to the target site (46%).
Imaging and treatment
Multi-modality imaging for staging and tumour assess-
ment is typically performed prior to SABR treatment,
Table 1 GYN SABR indications and number of respondents that
offer this type of treatment
GYN SABR Indications # of Respondents
Salvage Nodal 9
Salvage Pelvis/Primary 9
Cervical Boost 4
Endometrial Boost 4
Adjuvant Radiation 1
Vulva-Vaginal 2
Leung et al. Radiation Oncology           (2020) 15:24 Page 2 of 7
including computerized tomography (CT) (82%), posi-
tron emission tomography (PET-CT) (82%), magnetic
resonance imaging (MRI) (91%). For planning CT, slice
thickness of 2 mm or less is used (82%). Most common
organ motion strategies include fiducial markers (82%)
and bladder protocol (82%). Intravenous contrast is
often used with CT simulations (73%) with no routine
use of premedication. Common treatment delivery tech-
niques include VMAT (73%) and cyberknife (64%), with
some centres using both techniques. Photon energy
range between 6 MV to 18 MV.
Immobilization devices used include leg immobilizers
(36%) and full body fix vaclock (64%). Implanted fidu-
cials and kV x-rays are common for image guidance
(64%). Other techniques include cone-beam CT (45%),
robotic tracking (45%) and daily orthogonal KV x-rays
(36%), with some centres using multiple techniques.
Daily pre-treatment imaging and online correction is
used. Rotation correction errors of > 1–3mm are recom-
mended (91%), with repeat imaging after couch adjust-
ment (73%). Interfraction monitoring with fiducials is
also recommended but post-treatment imaging is rare
(45%). Checking pre-treatment imaging is important be-
fore each fraction (82%).
When chemotherapy is indicated, most respondents
treat sequentially (73%), with a break of at least 1–3
weeks. The remaining respondents do not typically treat
with SABR around the the time of systemic therapy.
Target definitions and OARs
When considering GYN SABR for recurrent nodal dis-
ease, the clinical target volume (CTV) is considered to
be the gross nodal disease with an expansion (73%)
whereas 9% considers the CTV to be the gross tumour
volume (GTV) only and another 9% considers the CTV
to be the GTV plus the nodal region at risk. A planning
target volume (PTV) expansion of 2–7 mm is typically
applied. For the CTV of recurrent primary disease (eg.
cervix), most treatment consider this to be the GTV or
an expansion on the GTV (36–46%). Of the 8
participants that have used SABR as a boost treatment, 3
defined the target as the GTV + cervix + grey zones
while the rest only treated the GTV +/− expansion.
PTV is often trimmed from organs at risk (OARs) to
avoid overlap (82%), however a safety margin on OARs,
or planning-at-risk-volumes (PRVs), is not typically used.
Coverage of PTV is most commonly 95%. For CTV, 95–
100% and GTV coverage is commonly 100%. Most com-
mon parameter used from planning optimization is
conformity indices (82%).
Target dose prescription is prescribed to the periphery
of the target (73%). Maximum hotspots can range be-
tween 105 and 200%. The isodose line covering the per-
iphery can range from 65 to 90%.
Dose fractionation and OAR constraints
Different fractionation doses and schedules are in prac-
tice for definitive SABR for recurrent disease and boost
SABR treatment after external beam radiation. Fraction-
ation regimens typically are between 3 and 5 fractions.
For recurrent nodal SABR, median dose is 36 Gy EQD2
(α/β = 10) (26.8–71.2). For recurrent primary SABR, me-
dian 40.4 EQD2 (α/β = 10) (27–71.2). For boost SABR after
standard pelvic radiation, Median 36.75 EQD2 (α/β = 10)
(15.6–60). Fractionation schedules for different centres
participating in this study are summarized in Table 2.
Typically, treatment is not on consecutive days and a
minimum 1-day gap is kept between fractions (73%).
OARs most commonly limited to a dose constraint in
GYN SABR include rectum, bladder, sigmoid, bowel,
spinal cord and kidney with most recommending small
bowel as the dose limiting organ (91%). A summary of
dose constraints used for GYN SABR are presented in
Table 3.
Follow-up and response
SABR follow-up done in clinic every 3, 6 or 12 months
with gynecological exam and investigations, including
MRI, PET and CT contrast. Imaging is typically done 2–
4 months after treatment to limit false positives from
Table 2 SABR Dose fractionations for different centres for 2 indications: 1) nodal recurrences, 2) recurrent primary tumours and 3)
primary boost
SABR Treatment Centre 1 Centre 2 Centre
3
Centre 4 Centre 5 Centre 6 Centre 7 Centre
8
Centre
9
Centre
10
Centre 11
Nodal Recurrence 8 Gy × 3
5 Gy × 5
5–8
Gy × 5
8 Gy ×
3
5–8 Gy × 3–5 5–7
Gy × 3
8–10
Gy × 5
11–13
Gy × 3
7.6–8 Gy ×
5
4 Gy ×
3
6 Gy ×
5
10
Gy × 3
5–6
Gy × 5
6–8 Gy ×
5
Recurrent Primary
Tumor
Does not
treat
5–8
Gy × 5
8 Gy ×
3
5–8 Gy × 3–5 5 Gy × 4
5 Gy × 5
8–10
Gy × 5
11–13
Gy × 3
7.6–8 Gy ×
5
4 Gy ×
3
6 Gy ×
5
10
Gy × 3
5–6
Gy × 5
6–8 Gy ×
5
Primary Boost NA 5 Gy ×
2–3
NA 5.5 Gy × 5
(median)
5–7
Gy × 3
8 Gy × 5 5–8 Gy ×
3–5
NA 7 Gy ×
4
7 Gy × 4 5.5–6
Gy × 5
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radiation changes. Local control is assessed through
RECIST criteria or negative PET scan. Post-treatment
biopsy is rare.
Discussion
To our knowledge, this is the first study summarizing
the practice and technological considerations of GYN
SABR among experts that practice and have published
on this technique [8, 10–21]. It is not intended to serve
as a consensus guideline. GYN SABR is routinely used
as a standard treatment option in a limited number of
centres with some indications only recommended on
clinical trial. Most common indications include salvage
treatment to the pelvis with most experts agreeing that
SABR should not be a replacement for brachytherapy.
Brachytherapy is known to be an effective treatment es-
sential to definitive treatment of locally advanced
gynecological disease and should not be substituted by
an external beam technique, including SABR. SABR
techniques are observed to vary among experts, particu-
larly dose fractionation and constraints, however, most
policies are consistent in imaging and immobilization
protocols.
As GYN SABR is becoming increasingly common in
practice, aligning international protocols may help guide
the establishment of this technique as one of the stand-
ard options for certain clinical indications. In the sys-
tematic review by Mendez et al., six major clinical
indications of GYN SABR were found in the published
literature [10]. These included SABR as treatment for
cervical cancer boost, endometrial cancer boost, salvage
nodal treatment, pelvic recurrences, adjuvant treatment
and vulvo-vaginal treatment. In this survey, salvage
treatment for nodes and pelvic recurrences (when
brachytherapy was contraindicated) were found to be
the most common standard indications for SABR. Previ-
ously published reports have found this to be an effective
treatment with local control rates above 80% [14, 22,
23]. Although some cases of isolated nodal recurrences
in previous non-irradiated fields could be potentially sal-
vaged with definitive chemoradiation treatment (and this
is still the traditional approach), salvage nodal SABR is
becoming more common in re-irradiation and oligome-
tastatic scenarios (Fig. 1). The respondents to the survey
(being heavily represented by an International affiliation)
also cited salvage nodal SABR as an acceptable ap-
proach. The incorporation of isolated nodal SABR with
added systemic therapy into current practice seems lo-
gical as it would allow rapid initiation of systemic ther-
apy following SABR, as compared to the traditional
approach of large field nodal salvage radiation which can
take weeks to complete.
It should be noted that the survey results don’t reflect
the more standard North American approach of salvage
extended field nodal radiation and more trials are
needed in this area before such practice is changed.
With the emergence of SABR treatment for oligometa-
static disease, there is increasing interest in this strategy
for GYN tumours [24]. Several non-randomized studies
and systematic reviews have shown a potential benefit of
SABR treatment for oligometastatic disease in other
solid tumours, such as breast, colorectal, lung and pros-
tate. These studies have generally demonstrated that
SABR for oligometastases yields high local control and
may confer improved disease survival [25–28]. SABR-
COMET was a phase II randomization between SABR
and standard of care palliative radiation. In 99 patients,
the study showed an improvement in survival within the
Table 3 OAR constraints from institutional policies of the 11 respondents of the survey. For 3 and 5 fraction SABR treatments
Dose constraints Constraint for 3 fxs Constraint for 5 fxs
OAR De novo De novo reRT
Rectum Dmax < 18–35 Gy
V60–90% < 10 - 24Gy
Dmax< 37.5 - 38Gy
D2cc < 38Gy
V25Gy < =10 cc
Dmax< 25 - 30Gy
D2cc < 32Gy
Bladder Dmax: < 20–40 Gy
V60–90% < 12- 24Gy
Dmax< 37.5–42 Gy
V35Gy < 5%
Dmax< 25 - 30Gy
D2cc < 36Gy
Sigmoid Dmax < 20–33 Gy Dmax < 39 - 40Gy
V25Gy < 20 cc
D2cc < 32Gy
Dmax< 25Gy
Large Bowel Dmax < 9–33 Gy Dmax< 38–40 Gy
D2cc < 34Gy
V25Gy < 20 cc
Dmax< 25 - 30Gy
D2cc < 32Gy
Small Bowel Dmax: 9–33 Gy
< 1 cc > 24Gy
V50% < 10Gy
Dmax< 35–39 Gy
V25Gy < 5 cc
Dmax< 15 - 25Gy
max
D2cc < 20Gy
Skin V60–95% < 12 - 24Gy
Kidney D200cc <16Gy
Dmax <15Gy
V50–90% < 10-14Gy
D200cc < 17.5Gy
mean < 10–11 Gy
V18Gy < 35%
mean < 10Gy
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SABR arm, but the study mostly included other solid
tumour types as there were only two patients in SABR-
COMET that had gynecological cancers. Median survival
in the SABR arm was 41months as compared with 28
months in the standard of care arm. However, it should
be noted that only 3 patients in the SABR arm had treat-
ment to nodal sites. Given the results of this survey and
the existing literature in nodal GYN SABR, there is
interest in prospectively studying oligometastases in
solely gynecological cancers [12, 14, 29].
Some would consider boost treatment with SABR,
however, most agree that this is only an option when
there is a contraindication to brachytherapy. Although
SABR can deliver high conformal doses of radiation to
the target, its ability to deliver high central pelvic doses
is still inferior to brachytherapy with current technolo-
gies and this can lead to suboptimal outcomes [7, 30]. In
the Mendez systematic review, it was found that vulvar
SABR was not common and has not been shown to be
effective, and this was consistent with only 2
Fig. 1 GYN SABR of recurrent nodal disease from endometrial cancer Nodal recurrence is bordering previous treatment field. Patient had previous
FIGO IB, Grade 2 endometrioid adenocarcinoma with multifocal LVSI (no nodes removed) treated with pelvic radiation 4 years prior to SABR
treatment. Prescription dose 35 Gy in 5 fractions
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respondents treating vulvar SABR off of clinical trials.
Adjuvant radiation using SABR instead of vaginal vault
brachytherapy was only used by 1 respondent.
Imaging and treatment protocols were found to vary
amongst the participating centres. GYN radiation on-
cologists have generally been late to adopt conformal
techniques due to concerns of significant degrees of
organ motion such as the cervix which has been
shown to move as much as 4 cm in the anterior-
posterior directions [31]. Therefore, most institutions
generally employ strategies to address organ and
tumour motion for SABR treatment including fidicual
markers and organ-filling protocols. Multi-modality
imaging was found to be essential due to the fact that
different GYN diseases are best delineated with have
different imaging modalities. For instance, soft tissue
pelvic tumours are optimally delineated on MRI and
while nodal disease are best appreciated on PET.
With the recent introduction of MRI-based LINAC
treatment systems, there is significant potential for
this technology to play a role in GYN SABR [32].
With the challenge of organ motion in GYN tumours,
MRI may help address this issue through on-line and
real-time imaging.
CTV definitions were generally similar among partici-
pants with some using brachytherapy contouring guide-
lines to define targets in the central pelvis. Dose
fractionation varied for different indications and varied
among participants with most using 3–5 fractions for
SABR treatment. There was also a wide variation of
OAR constraints used with most treatment target
constraints being similar in both the de novo and re-
irradiation setting. These constraints reflect the institu-
tional practices of the respondents and are not intended
to serve as a consensus guideline for GYN SABR plan-
ning. Well-researched dose constraints that are not spe-
cific to GYN SABR include the AAPM-101 report and
the more recent updated UK Consensus [33, 34]. Further
research into toxicities and OAR tolerance specific to
GYN SABR is needed .
Conclusions
GYN SABR is commonly used in specialized centres
around the world. Although SABR can deliver high-dose
conformal radiation to targets, most experts agree that it
is only used as a definitive boost treatment when brachy-
therapy is contraindicated. SABR for nodal and pelvic
tumour salvage is becoming one of the common treat-
ments and dose-fractionation and OAR tolerances vary
among different centres. Future collaborative studies and
clinic trials are warranted to better define the role and
to standardize the practice of SABR for gynecological
malignancies.
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